echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Coronavirus disease does not increase the short-term risk of clinical recurrence of multiple sclerosis

    JNNP: Coronavirus disease does not increase the short-term risk of clinical recurrence of multiple sclerosis

    • Last Update: 2021-09-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Multiple sclerosis (MS) is the most common type of central nerve demyelination disease


    Multiple sclerosis (MS) is the most common type of central nerve demyelination disease


    25 Italian MS patients participated in this prospective, multi-center observational study.


    This article was published in " Journal of Neurology, Neurosurgery & Psychiatry " ( Journal of Neurology, Neurosurgery & Psychiatry )


    3 24 pwMS vaccinated with Swiss/BioNTech BNT162b2 vaccine


    24 pwMS vaccinated with Swiss/BioNTech BNT162b2 vaccine


    Patient characteristics

    The safety of vaccines in PWMS has always been the focus of controversy


    Our preliminary analysis indicated that the Pfizer/BioNTech BNT162b2 vaccine does not increase the short-term risk of clinical reactivation of pwMS


    Di FilippoM ,CordioliC ,MalucchiS Di FilippoMDi Filippo CordioliCCordioli MalucchiSMalucchi, et almRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry  Published Online First:  18 August 2021.
     Published Online First: doi:  10.
    1136/jnnp-2021-327200doi:

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.